Funder: Bill and Melinda Gates Foundation
Due Dates: January 31, 2025 (Option A) | May 31, 2025 (Option B)
Funding Amounts: Up to $750,000 USD per project (Option A, up to 18 months); Option B funding and duration determined per project.
Summary: Funds innovative approaches to reduce monoclonal antibody production costs to $10/g, aiming to expand access in low- and middle-income countries.
Key Information: Applicants may only apply to one option; only organizations (not individuals) are eligible.